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Background: We evaluated pharmacodynamic changes in tumour perfusion using positron emission tomography
(PET) imaging with 15O-water to assess biological response to sunitinib, a multitargeted tyrosine kinase inhibitor.
Methods: Patients with advanced malignancies received sunitinib 50 mg/day orally, once daily for 4 weeks on
treatment, followed by 2 weeks off treatment, in repeated 6-week cycles. Quantitative measurement of tumour
perfusion was assessed using 15O-water-PET at baseline and after 2 weeks of treatment. At least one reference
tumour lesion was included in the fields of view and assessed at both time points. Patients also underwent 18 F-
fluorodeoxyglucose (FDG)-PET imaging at baseline and after 2 and 4 weeks of treatment. Radiological response of
the reference tumour lesion and overall radiological response were assessed at week 12. Serum pharmacokinetic
and biomarker analyses were also performed.
Results: Data were available for seven patients. Compared with baseline, all patients experienced a decrease in
reference tumour blood flow ranging from 20 % to 85 % and also a reduction in the FDG standard uptake value
ranging from 29 % to 67 %. Six patients experienced a partial metabolic response based on FDG-PET criteria. Four
patients had stable disease defined by radiological response (Response Evaluation Criteria in Solid Tumors) lasting
between 4 and 12 cycles. An association between perfusion change and clinical benefit, and biomarker levels
including vascular endothelial growth factor was observed.
Conclusion: Administering sunitinib to patients with advanced malignancies is associated with early biological
responses, including decreased blood flow in secondary tumour deposits.
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Once solid tumours have reached an advanced or
metastatic stage, treatment is largely palliative rather
than curative, with the aim of prolonging survival, reliev-
ing pain and other symptoms, and maintaining or im-
proving quality of life [1-3]. Pharmacotherapy at such
advanced stages is generally targeted at slowing, halting,* Correspondence: andrew.scott@ludwig.edu.au
1Centre for PET, Ludwig Institute for Cancer Research and Ludwig Oncology
Unit, Austin Hospital, Studley Road, Heidelberg, Victoria 3084, Australia
Full list of author information is available at the end of the article
© 2012 Scott et al.; licensee Springer This is an
Attribution License (http://creativecommons.or
in any medium, provided the original work is por - if possible - reversing tumour progression, and at
reducing the chance of further metastasis.
Targeted biological therapies with antiangiogenic
properties may be particularly beneficial in the palliative
care setting by preventing the neovascularisation
required for tumour progression beyond a certain size
[4]. The early and more subtle biological effects of new
antiangiogenic agents may not be detected by conven-
tional measures of tumour response, which are based on
changes in tumour size. Positron emission tomography
(PET) imaging assesses functional aspects of tumour
status and may detect biological responses (e.g.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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in tumour size are apparent with conventional imaging
techniques [5,6].
Sunitinib (SutentW; Pfizer Inc., New York, NY, USA) is
an orally active, multitargeted tyrosine kinase inhibitor
with both antitumour and antiangiogenic effects. Its
targets include vascular endothelial growth factor recep-
tors 1, 2, and 3 (VEGFRs-1, -2, and −3), platelet-derived
growth factor receptors α and β, stem-cell factor recep-
tor, FMS-like tyrosine kinase 3, and glial cell line-derived
neurotrophic factor receptor [7-12]. Sunitinib is
approved in many countries for the treatment of gastro-
intestinal stromal tumours after disease progression on
or intolerance to imatinib mesylate therapy [13], for the
treatment of advanced renal cell carcinoma [14], and for
the treatment of advanced pancreatic neuroendocrine
tumours [15].
In a pilot study of 55 adults with advanced malignan-
cies treated with sunitinib, biological activity and antitu-
mour effects were seen in a broad range of tumour types
[16]. Seven patients continued therapy for more than
12 months, and two patients remained on therapy more
than 3 years after enrolment. Two types of antitumour
activity were seen: tumour shrinkage and central tumour
necrosis. Serial PET imaging detected ≥20 % reductions
in the standard uptake value (SUV) of 18 F-fluoro-2-
deoxy-D-glucose (FDG) as early as the second week of
treatment. Both PET response and clinical benefit corre-
lated with trough plasma levels of sunitinib and its
principal metabolite (SU12662). The present paper
reports on a subset of seven patients from this study
who, in addition to standard study procedures, also
underwent pharmacodynamic assessment with quantita-
tive 15O-water-PET imaging to assess the effects of
sunitinib treatment on tumour perfusion.
Methods
Patients and treatment
The use of FDG-PET and other PET-based imaging
techniques to assess biological response to sunitinib was
investigated in a 12-week, open-label, prospective pilot
study involving four groups. The present study describes
the group of patients who underwent 15O-water- and
FDG-PET imaging. All patients were ≥18 years old, with
radiological evidence of metastatic or advanced malig-
nancy for which there was no available therapy with
curative potential. Other key eligibility criteria included
Karnofsky performance status> 60 %, life expectancy
> 12 weeks without rapidly progressive disease, and
adequate liver function (aspartate transaminase (AST) or
alanine transaminase (ALT)≤ 2.5 × upper limit of normal
(ULN); AST or ALT ≤ 5.0 ×ULN or bilirubin ≤ 1.5 ×ULN
if liver function abnormalities were due to underlying
malignancy), renal function (serum creatinine ≤ 1.5 ×ULN or calculated creatinine clearance> 40 mL/min by
the Cockcroft-Gault formula), and bone marrow
function (absolute neutrophil count (ANC)≥ 1.5 × 109/L,
platelets ≥ 75 × 109/L, and haemoglobin> 10 g/L; ANC ≥
1.0 × 109/L, platelets≥ 50 × 109/L, or haemoglobin> 10
g/L for patients with haematological malignancies and
bone marrow involvement). At screening, all patients
had to have at least one tumour mass detectable by
FDG-PET imaging that was suitable for serial quantita-
tive assessment and had not been included in a prior
radiotherapy field. Female patients were postmenopau-
sal, surgically sterile, or using effective contraception.
Key exclusion criteria included the use of any other
anticancer agent or investigational agent within 4 weeks
prior to the start of sunitinib treatment, prior specific
anti-vascular endothelial growth factor (VEGF) treat-
ment, and any condition requiring treatment that was
likely to affect the reliability of the serial PET assess-
ments. Patients were also excluded if they had a medical
or psychiatric condition that would limit full compliance
with the study. Concomitant treatments necessary for
the patients' well-being were given at the discretion of
the investigator. The study was carried out in accord-
ance with the International Conference on Harmonisa-
tion Good Clinical Practice guidelines and was approved
by an institutional review board. All patients provided
written informed consent.
Patients received oral sunitinib 50 mg once daily for
4 weeks on treatment, followed by 2 weeks off treatment
(schedule 4/2) in repeated 6-week cycles. The primary
study period was the first two cycles (12 weeks) of treat-
ment. Patients benefiting from the treatment were per-
mitted to receive additional cycles of sunitinib for up to
1 year. The study drug was discontinued in patients
exhibiting grade 4 haematological toxicity, grade 3
thrombocytopenia with haemorrhage of grade 3/4, or
grade 3/4 non-haematological toxicity, and only
restarted when the ANC recovered to ≥ 1.5 × 109/L and
platelet count to 75 × 109/L.
Study assessments
Tumour perfusion
Tumour perfusion was assessed using a radioactive
tracer (15O-water) and PET imaging. This technique
allowed quantification of the arterial concentration of
15O-water and calculation of the perfusion rate. Quanti-
fication of blood flow within the tumour (expressed in
milliliter per gram per minute) was performed.
15O-water-PET imaging was performed at baseline and
after 2 weeks of treatment using an ECAT 951/31R
scanner ( CTI PET Systems, Knoxville, TN, USA),
employing 16 rings of bismuth germanate oxide block
detectors with an axial extent of 108 mm and a spatial
resolution of 5.4 mm at the scanner's centre of field of
Scott et al. EJNMMI Research 2012, 2:31 Page 3 of 10
http://www.ejnmmires.com/content/2/1/31view. At least one viable reference tumour lesion identi-
fied by FDG-PET scanning was included in the field of
view and was assessed at both time points. Emission
scans were acquired dynamically in three-dimensional
(3D) mode during bolus intravenous injections of
370 MBq of 15O-water into the antecubital vein. The dy-
namic acquisition consisted of 11 frames acquired over
3 min with 4 × 5-s, 2 × 10-s, and 4 × 30-s frames. A trans-
mission image (10-min acquisition) was also obtained.
Dynamic dataset images were reconstructed with both
3D-filtered back-projection, using a 3D reprojection al-
gorithm (3D-FORE/FBP), and 3D attenuation-weighted
ordered-subsets expectation maximisation (AW-
OSEM3D) [17,18]. As a result of the superior image
quality of the AW-OSEM3D reconstruction, this was
used for the subsequent analysis.
Glucose uptake
All patients had an FDG-PET scan at screening, up
to 14 days prior to commencing sunitinib treatment.
Further FDG-PET scans were performed at baseline
and after 2 and 4 weeks of treatment, with SUV
measurement of the glucose metabolism of both
reference and overall tumour lesions. Whole body
FDG-PET scanning was performed using a Philips
Allegro dedicated PET scanner (Philips Medical
Systems, Cleveland, Ohio, USA) under standardised
conditions, following an overnight fast, and with im-
aging commencing exactly 60 min after FDG admin-
istration. All studies were performed with measured
attenuation correction and were reconstructed using
RAMLA 3D [19] and reconstructed in units of SUV.
Blood glucose and lean body mass were recorded.
Overall response (OR) was assessed in patients com-
pleting at least 4 weeks of treatment with all assess-
ments performed. OR was defined as a ≥20 %
reduction in FDG uptake as assessed by SUV cor-
rected for lean body mass in all lesions present at
baseline in the absence of any new lesions. Progres-
sive disease (PD) was defined as a ≥15 % increase in
FDG uptake in any lesion or emergence of any new
lesions. A mixed response was defined as multiple
lesions with an OR or PD, plus other lesions with
stable disease.
Image analysis of tumour perfusion
The volume of interest (VOI) for the reference tumour
for each patient was defined using the FDG-PET data by
thresholding to approximately 75 % of the maximum
SUV in tumour and also by comparing to tumour size
on computed tomography scan. The VOIs were defined
for the baseline and 2-week post-treatment 15O-water
studies using the associated baseline and 2-week post-
treatment FDG scan-determined VOIs. The entire VOIwas used to determine the activity for 15O-water. By
using the attenuation image for the FDG and 15O-water
studies, the emission images from both studies were co-
registered so that the reference tumour VOIs could be
applied to the water study (Figure 1). A summed
dynamic image from the 15O-water study was then used
to define the descending aorta. The resultant tumour
and aortic VOIs were used to determine the integrated
activity for their respective regions, which then defined
the response and input functions, respectively.
Spectral analysis
A one-tissue compartment model was used to calculate
the tumour blood flow and comprised vascular and
tissue compartments (Figure 2a). The operational
equation defining tissue blood flow is given in Figure 2b,
c, where M(t) denotes the detected activity within a VOI
and is made up of a vascular component given by V0Ca
(t) and an extra-vascular or tissue component Me(t),
where V0 denotes the vascular volume term, and Ca(t),
the arterial input term. Such a system is governed by a
so-called one-tissue-compartment model dictated by the
equation given in Figure 2c, where K1 denotes the blood
perfusion from vascular to tissue compartment, and k2,
the washout rate, as illustrated in Figure 2. The analytic
solution to this differential equation is expressed in Fig-
ure 2d. Non-linear analytical techniques are adopted to
solve for the rate constants K1 and k2.
For the purposes of this analysis, tumour blood perfu-
sion was derived from this equation by using the tumour
VOI to input data into the tissue compartment of this
model. Normally, the vascular compartment is neglected
in this model as it generally makes a small contribution
(approximately 5 %) to the net activity, thus reducing
the analysis to a single-compartment model. However,
for tumour regions, the high vascular density requires
this term to be explicitly modelled [20]. Thus, both tis-
sue perfusion and blood volume were determined.
Spectral techniques were adopted in the analysis of
tumour blood flow data due to the robustness of the lin-
ear approach and the input/response function delays.
The equation in Figure 2e illustrates the linearisation
process whereby a spectrum of exponentials convolved
with the input function are predetermined so as to allow
the linear solution for the blood-perfusion weighting
terms given by αi. By adopting such a spectrum of expo-
nentials, the problem is linearised and, so, is less prone
to noise effects in the measured data. The vascular term
is incorporated implicitly by ranging the spectrum of
exponentials from βi = 0 to a predetermined maximum
flow rate. Upon solving this system using standard linear
techniques, the blood perfusion + vascular volume of the
tumour is determined by summing the spectrum of αi
components.
Figure 2 Spectral analysis model and operational equations. Spectral analysis model used to calculate tumour blood flow comprising
vascular and tissue compartments (a), and the operational equation defining tissue blood flow (b) and (c) where M(t) denotes the detected
activity within a volume of interest and is made up of a vascular component given by V0Ca(t) and an extra-vascular or tissue component Me(t),
where V0 denotes the vascular volume term, and Ca(t), the arterial input term. Such a system is governed by a so-called one-tissue-compartment
model dictated by the equation given in (c). The analytic solution to this differential equation is expressed in (d). The equation in (e) illustrates
the linearisation process whereby a spectrum of exponentials convolved with the input function are predetermined so as to allow the linear
solution for the blood-perfusion weighting terms given by αi.
Figure 1 Reference tumour volume of interest using the attenuation image for the FDG and 15O-water studies. Liver metastasis defined
on the FDG-PET emission image ((a) coronal and (d) transaxial), also seen on the CT scan (c), was identified and transposed onto the 15O-water
acquired attenuation image ((b) coronal and (e) transaxial) to be subsequently applied to the dynamic 15O-water emission image. The
descending aorta volume of interest markup from 15O-water early dynamic frames ((f) transaxial and (g) coronal)
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Radiological response of the reference tumour lesion
and overall radiological response were assessed at week
12 using Response Evaluation Criteria in Solid Tumors
(RECIST) [21]. Clinical benefit was deemed to be
present if the treating clinician judged that the patient
was benefiting from treatment (RECIST-defined stable
disease or response) and continued the therapy beyond
the 12-week study period. Formal response evaluation
and clinical benefit assessment were performed every
12 weeks for patients continuing to receive sunitinib
after the second cycle of treatment.
Pharmacokinetic and biomarker analyses
Blood samples for analysis of pharmacokinetic para-
meters were collected on day 1 and every 14 days in
cycle 1. Levels of sunitinib and its principal metabolite,
SU12662, were determined using liquid chromatography
and mass spectrometry techniques. Peripheral blood for
biomarker analysis was collected before and 6 h after the
first dose on day 1 and at every visit thereafter (i.e., every
14 days for the first 12 weeks). Samples were screened
by enzyme-linked immunosorbent assays and 2D-gel
electrophoresis for proteins whose levels may be altered
in association with sunitinib activity or exposure: for ex-
ample, VEGF and soluble VEGFR-2 (sVEGFR-2).
Statistical analysis
Data were summarised using descriptive statistics. Ana-
lysis of change in tumour perfusion or FDG-SUV was
performed using the Student's t test, comparing patients
with clinical benefit to those without clinical benefit of
treatment (one-sided t test, assumed unequal variance).
Analysis of day 15 trough levels of sunitinib plus
SU12662 was performed using a z-test for patients with














1 Renal Right hepatic lobe −85 −39
2 Colon Right hepatic lesion −77 −37
3 Colon Right hepatic lobe −59 −33
4 Colon Right hepatic lobe −34 −44
5 NSCLC Left lung lesion −69 −67
6 Colon Right hepatic lesion −38 −32
7 Oesophageal Right hepatic dome −20 −29
Biological (week 2) and radiological (week 12) responses among patients with adva
on treatment followed by 2 weeks off treatment (schedule 4/2). Clinical benefit was
benefiting from treatment and continued therapy beyond the 12-week study perio
emission tomography; FDG-SUV, 18 F-fluorodeoxyglucose standard uptake value; NSa reference of 50 ng/mL. Linear relationships between
change in tumour perfusion or change in FDG-SUV and
biomarker levels were determined using Pearson's prod-
uct moment correlation with 95 % confidence intervals.Results
Data are reported for seven patients who underwent all
study investigations and completed at least two treat-
ment cycles (Table 1). Dosing was delayed for patients 2
and 3 before starting cycle 2 of therapy, while the cycle
2 dose of patient 7 was reduced by 25 %. Figure 3 illus-
trates the result of the spectral fitting procedure for pa-
tient 4 for pre- and post-treatment, with the associated
estimation of tumour blood reported in the value of K1.
Partial volume effects were not considered as the
tumour VOIs were of similar size for both pre- and
post-treatment.
Table 1 details the site of the primary and reference
tumours as well as the biological and radiological re-
sponse of the reference tumour and overall tumour re-
sponse to sunitinib therapy. All patients exhibited a
decrease in reference tumour blood flow, ranging from
20 % to 85 %, and a reduction in FDG-SUV from
baseline in the reference tumour, ranging from 29 % to
67 %. Six of the seven patients experienced a partial
metabolic response at week 4 based on FDG-PET
criteria. Four patients had stable disease lasting between
four cycles (24 weeks) and 12 cycles (72 weeks)
confirmed by RECIST at restaging.
Further analyses were undertaken in order to investi-
gate potential correlations between percent reduction in
tumour perfusion and clinical benefit, duration of ther-
apy, percent reduction in FDG-SUV, plasma levels of
sunitinib and SU12662, and changes in plasma levels of
VEGF and sVEGFR-2 (Table 2, Figures 4 and 5). There




















Yes SD SD 4 Yes
Yes SD SD 6 Yes
Yes PD PD 2 No
Yes PD PD 2 No
Yes SD SD 12 Yes
Yes SD SD 7 Yes
No PD PD 2 No
nced malignancies treated with sunitinib 50 mg given once daily for 4 weeks
deemed to be present if the treating clinician judged that the patient was
d. D15:D1, day15:day1 ratio; FDG-PET, 18 F-fluorodeoxyglucose positron
CLC, non-small cell lung cancer; PD, progressive disease; SD, stable disease.
Table 2 Change in tumour perfusion, FDG-SUV, clinical benef

















1 0.81 −85 4.6 −39 −48
2 1.18 −77 6.5 −37 −59
3 1.52 −59 4.2 −33 −29
4 1.28 −34 9.8 −44 −13
5 0.74 −69 12.3 −67 −66
6 1.39 −38 6.0 −32 −18
7 1.23 −20 4.1 −29 −41
aClinical benefit was deemed to be present if the treating clinician judged that the
week study period. bTarget trough level for therapeutic effect was considered> 50
uptake value; NA, not available; VEGF, vascular endothelial growth factor; sVEGFR-2
Figure 3 Tumour blood flow analysis in patient 4. The result of
the spectral fitting procedure for patient 4 pre-treatment (a) and
post-treatment (b), with the associated estimation of tumour blood
perfusion reported in the value of K1.
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and subsequent clinical benefit (t test, p= 0.05; Figure 4a)
as well as with duration of therapy (Figure 4b) and with
change in biomarker levels, particularly VEGF (Fig-
ures 5b,c). A further non-significant trend was observed
between VEGF biomarker levels and FDG-SUV (percent)
change (sVEGFR2: r= 0.76, p> 0.05 and VEGF:
r=−0.75, p> 0.05). In this study, there was no evidence
of correlation between the degree of change in tumour
perfusion with the degree of FDG-SUV change
(r=−0.09, p> 0.05; Figure 4c) or with trough levels of
sunitinib plus SU12662 (Figure 5a). However, when
comparing trough levels of sunitinib plus SU12662 with
a clinical reference of 50 ng/mL, there was a significant
change in levels in responsive patients (p< 0.001) com-
pared with those in patients who were not responsive to
the therapy (p= 0.38).Discussion
The results of this study conclusively show that sunitinib
treatment of adult patients with a variety of metastatic
malignancies is associated with early biological
responses, including decreased blood flow in secondary
tumour deposits. The reduction in tumour blood flow
was associated with a corresponding fall in FDG-SUV,
consistent with a decrease in tumour metabolic rate.
This is the first study to provide quantitative evidence of
the pharmacodynamic effects of sunitinib on tumour
blood flow by PET imaging. There was also a possible
association between the degree of change in tumour per-
fusion measured after 2 weeks of therapy and subse-
quent clinical benefit, duration of therapy, and change in
levels of the biomarker VEGF. Blockade of VEGFR
signalling by sunitinib may lead to reduced VEGF uptake
by VEGFR and, hence, increased circulating VEGF,

















Yes 76.4 5.29 0.66
Yes 134.9 4.85 0.44
No 90.8 8.67 0.34
No 27.6 2.56 0.75
Yes 107.1 4.17 0.49
Yes 88.8 NA NA
No 105.0 NA NA
patient was benefiting from treatment and continued therapy beyond the 12-
ng/mL. D15:D1, day 15:day 1 ratio; FDG-SUV, 18 F-fluorodeoxyglucose standard
, soluble vascular endothelial growth factor receptor 2.
Figure 4 Correlation between reduction in tumour perfusion
and clinical benefit, duration of therapy, and FDG-SUV change.
Potential correlations between percent reduction in tumour
perfusion and clinical benefit (p= 0.05) (a), duration of therapy
(p= 0.05) (b), and percent reduction in FDG-SUV (p> 0.05) (c).
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went on to have a conventional tumour response. Pos-
sible explanations for this lack of correlation include a
mismatched assessment timing for tumour perfusion (at
2 weeks) and radiological response (at 12 weeks), allow-
ing for tumour progression after an initial early re-
sponse. Dosing was delayed in one patient, and the dose
was reduced in another of the three patients with
progressive disease at 12 weeks, which may have influ-
enced the clinical tumour response despite an earlier
decrease in tumour perfusion. Mixed responses, with the
reference tumour showing a response but other tumour
deposits showing progression, and stable or enlarging
tumour masses despite central necrosis, could also
account for the observed lack of correlation between
tumour perfusion and conventional response. In this
context, PET imaging may be informative regarding ini-
tial pharmacodynamic changes in response to sunitinib
treatment, but may not be predictive of the final
response.
The methodology used in this study for assessing
tumour perfusion changes was based on established
techniques and adapted to enable quantitative analysis of
tumour perfusion with 15O-water-PET without requiring
an arterial line. The use of 15O-water-PET for the quan-
titation of blood flow is well established; it is a reliable
method to assess the pharmacodynamics of therapeutic
agents with a mechanism of action involving angiogen-
esis inhibition [22]. The short half-life of 15O-water does
restrict its use to PET centres with on-site cyclotrons.
Additional limitations of this study that preclude defini-
tive conclusions include the small sample size and
heterogeneous nature of the cases. In addition, there
may be a sampling error associated with the selection of
target lesions when multiple lesions are present.
Blood flow in solid tumours is often increased relative
to the surrounding tissue [23-25]. Moreover, tumour
progression beyond a certain size requires active angio-
genesis, making antiangiogenic therapy an attractive
target for new drug development. Previous studies have
indicated a relationship between clinical response, in
terms of disease-free survival, and a combination of
FDG and tumour perfusion measurements in patients
receiving chemotherapy for advanced breast cancer [23].
The role of VEGF-PET as a biomarker of dynamic angio-
genic changes has recently been investigated [26]. The
effects of sunitinib treatment were assessed using the
VEGF-PET tracer 89Zr-ranibizumab in mouse xenograft
models of human cancer. VEGF-PET demonstrated
dynamic changes during sunitinib treatment, with a
strong decline in signal in the tumour centre and only
minimal reduction in the tumour rim, with a
pronounced rebound after sunitinib discontinuation. In
Figure 5 Correlation between reduction in tumour perfusion and trough levels of total drug, VEGF, and sVEGFR-2. Potential correlations
between percent reduction in tumour perfusion and day 15 trough levels of total drug (sunitinib plus SU12662; p> 0.05) (a), change in plasma
VEGF levels (p= 0.05) (b), and change in plasma sVEGFR-2 levels (p> 0.05) (c). D15:D1, day 15:day 1 ratio.
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growth and immunohistochemical vascular and tumour
markers.
Conclusions
The results presented here indicate that sunitinib
therapy is associated with early biological responses and
measurable pharmacodynamic changes in tumour blood
flow and metabolism. These data provide important new
insights into the antitumour effects of sunitinib in this
patient population.
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